Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-5b777bbd6c-4n89n Total loading time: 0 Render date: 2025-06-25T16:59:02.135Z Has data issue: false hasContentIssue false

Chapter 25 - Use of botulinum neurotoxin in neuropathic pain

Published online by Cambridge University Press:  05 February 2014

By
Szu-Kuan Yang  and
Chaur-Jong Hu
Edited by
Daniel Truong ,
Dirk Dressler ,
Mark Hallett  and
Christopher Zachary
Szu-Kuan Yang
Affiliation:
Department of Neurology, Shuang-Ho Hospital, Taipei Medical University, New Taipei City, Taiwan
Chaur-Jong Hu
Affiliation:
Department of Neurology, Shuang-Ho Hospital, Taipei Medical University, New Taipei City, Taiwan
Daniel Truong
Affiliation:
The Parkinson’s and Movement Disorders Institute, Fountain Valley, California
Dirk Dressler
Affiliation:
Department of Neurology, Hannover University Medical School
Mark Hallett
Affiliation:
George Washington University School of Medicine and Health Sciences, Washington, DC
Christopher Zachary
Affiliation:
Department of Dermatology, University of California, Irvine
Get access

Summary

Introduction

Botulinum neurotoxin (BoNT) has been used effectively to alleviate pain in many pain disorders and has been proven to be a good choice for treatment of neuropathic pain. There have been no major side effects, only minor local infection. Randomized controlled studies and open-label studies indicate BoNT is beneficial in diabetic neuropathic pain, trigeminal neuralgia and postherpetic neuralgia (Piovesan et al., 2005; Ranoux et al., 2008; Yuan et al., 2009; Xiao et al., 2010). This chapter discusses the putative mechanisms of BoNT action and injection methodology for these three conditions.

Peripheral and central sensitization processes are involved in the pathophysiology of neuropathic pain (Baron, 2006; Pace et al., 2006). Abnormal muscle contraction, released substance P and calcitonin gene-related peptide also play significant roles in hyperalgesia of neuropathic pain. An ideal therapy for neuropathic pain should block these pain-inducing pathways as completely as possible. Muscle paralytic mechanisms, vasodilatation, pain-related neurotransmitter blockage, peripheral inflammatory pain inhibition and the inhibition of central pain perception contribute to the effectiveness of BoNT for neuropathic pain (Ranoux et al., 2008; Yuan et al., 2009; Neumeister et al., 2009).

Type
Chapter
Information
Manual of Botulinum Toxin Therapy , pp. 216 - 221
Publisher: Cambridge University Press
Print publication year: 2014

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Aoki, KR (2005). Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology, 26, 785–93.CrossRefGoogle ScholarPubMed
Argoff, CE, Katz, N, Backonja, M (2004). Treatment of postherpetic neuralgia: a review of therapeutic options. J Pain Symptom Manage, 28, 396–411.CrossRefGoogle ScholarPubMed
Baron, R (2006). Mechanisms of disease: neuropathic pain a clinical perspective. Nat Clin Pract Neurol, 2, 95–106.CrossRefGoogle ScholarPubMed
Cui, M, Khanijou, S, Rubino, J, Aoki, KR (2004). Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain, 107, 125–33.CrossRefGoogle ScholarPubMed
Davies, M, Brophy, S, Williams, R, Taylor, A (2006). The prevalence, severity and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care, 29, 1518–22.CrossRefGoogle ScholarPubMed
Ford, AP, Gever, JR, Nunn, PA et al. (2006). Purinoceptors as therapeutic targets for lower urinary tract dysfunction. Br J Pharmacol, 147, S132–43.Google ScholarPubMed
Gunn, CC (2001). Neuropathic myofascial pain syndromes. In Loeser, JD (ed.) Bonica’s Management of Pain. Philadelphia, PA: Lippincott, Williams & Wilkins, pp. 522–9.Google Scholar
Jabbari, B, Machado, D (2011). Treatment of refractory pain with botulinum toxins: an evidence-based review. Pain Med, 12, 1594–606.CrossRefGoogle Scholar
Morenilla-Palao, C, Planells-Cases, R, García-Sanz, N, Ferrer-Montiel, A (2004). Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J Biol Chem, 279, 25665–72.CrossRefGoogle ScholarPubMed
Neumeister, MW, Chambers, CB, Herron, MS et al. (2009). Botox therapy for ischemic digits. Plast Reconstr Surg, 124, 191–201.CrossRefGoogle ScholarPubMed
Opstelten, W, Mauritz, JW, de Wit, NJ et al. (2002). Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract, 19, 471–5.CrossRefGoogle ScholarPubMed
Pace, MC, Mazzariello, L, Passavanti, MB et al. (2006). Neurobiology of pain. J Cell Physiol, 209, 8–12.CrossRefGoogle Scholar
Paukert, M, Osteroth, R, Geisler, HS et al. (2001). Inflammatory mediators potentiate ATP-gated channels through the P2X(3) subunit. J Biol Chem, 276, 21077–82.CrossRefGoogle ScholarPubMed
Petrenko, AB, Yamakura, T, Baba, H, Shimoji, K (2003). The role of N-methyl-d-aspartate (NMDA) receptors in pain a review. Anesth Analg, 97, 1108–16.Google ScholarPubMed
Piovesan, EJ, Teive, HG, Kowacs, PA et al. (2005). An open study of botulinum A toxin treatment of trigeminal neuralgia. Neurology, 65, 1306–8.CrossRefGoogle ScholarPubMed
Ranoux, D, Attal, N, Morain, F, Bouhassira, D (2008). Botulinumtoxin typeA induces direct analgesic effects in chronic neuropathic pain. Ann Neurol, 64, 274–83.CrossRefGoogle Scholar
Sampathkumar, P, Drage, LA, Martin, DP (2009). Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc, 84, 274–80.CrossRefGoogle ScholarPubMed
Turk, U, Ilhan, S, Alp, R, Sur, H (2005). Botulinum toxin and intractable trigeminal neuralgia. Clin Neuropharmacol, 28, 161–2.Google ScholarPubMed
Van, Beek AL, Lim, PK, Gear, AJL, Pritzker, MR (2007). Management of vasospastic disorders with botulinum toxin A. Plast Reconstr Surg, 119, 217–26.Google Scholar
Xiao, L, Mackey, S, Hui, H et al. (2010). Subcutaneous injection of botulinum toxin A is beneficial in postherpetic neuralgia. Pain Med, 11, 1827–33.CrossRefGoogle ScholarPubMed
Yuan, RY, Sheu, JJ, Yu, JM et al. (2009). Botulinum toxin for diabetic neuropathic pain a randomized double-blind crossover trial. Neurology, 72, 1473–8.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×